Refer to previous post - efficacy signals ! MBA was 1/5 secondary's used
Cgi (clinician based) and rsbq (also clinically validated) plus rtt-dsc all showed a stastistical benefit ... or efficacy signal
The pre chosen p3 endpoint will change but that's the point of p2/2b ... to determine what the best path forward is and this is determined by final results . Neu should not have chosen the p3 endpoint immediately after p2 .
Whether you love/hate neuren or any biotech you can't argue with that. Give me a challenge and post some intellectually stimulating that is worth debating .
Neuren just had some weetbix :0), page-20
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |